Remove Medicine Remove Pharma Companies Remove Pharma Production Remove Research
article thumbnail

Cardiac and Diabetic PCD Pharma Franchise Company in India

Fossil Remedies

As the number of people affected by these problems is increasing, there is a high demand for medicines required to treat them. If you are planning to launch Cardiac Diabetic PCD Pharma Franchise, then it is the best time. You need an ISO-confirmed company that has WHO and GMP certification also.

article thumbnail

Brazil: untapped market for big pharma manufacturing

Pharmaceutical Technology

SUS provides full, free and universal access to healthcare for the country's entire population (215 million), which spends around 10% of its gross domestic product (GDP) on healthcare. Only a limited number of international pharma companies, however, operate manufacturing sites in the country.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Brexit fallout continues with batch testing concerns

Pharmaceutical Technology

In principle, the deal could create new opportunities for British pharma companies – not least the chance to work under a more supportive regulatory framework. Among the negative effects that have been reported are supply chain disruptions, skills shortages, issues around market authorisation, and added costs for pharma CMOs.

Medicine 290
article thumbnail

Ep. 006 – Mark Stinson & Bob Baurys Podcast Transcript

Pharma Marketing Network

My background for decades now is in the pharma marketing and branding space, working with all sorts of pharma products, devices, diagnostics. Working in both marketing and advertising campaigns but also market research, strategic planning, workshop facilitation. Is it the scientific researchers? Don (PMN): Great.

Doctors 40
article thumbnail

‘Right shoring’ API production in Europe

Pharmaceutical Technology

Only 25% of API production for generic drugs took place in Europe in 2020, according to a November 2022 Medicines for Europe report. For innovative medicines, this share was 77%.